{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:06:33Z","timestamp":1790431593238,"version":"4.1.0"},"reference-count":254,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2018.00167","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T09:40:36Z","timestamp":1520415636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":151,"title":["Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective"],"prefix":"10.3389","volume":"9","author":[{"given":"Gilda","family":"Varricchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Cadeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mercuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G.","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jat.782","article-title":"Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats","volume":"21","author":"Abd El-Aziz","year":"2001","journal-title":"J. Appl. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.breast.2014.04.002","article-title":"Cardiotoxicity of systemic agents used in breast cancer","volume":"23","author":"Ades","year":"2014","journal-title":"Breast"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-fluorouracil","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1111\/bph.13725","article-title":"5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1","volume":"174","author":"Altieri","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/nbm.1370","article-title":"Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein","volume":"22","author":"Andreadou","year":"2009","journal-title":"NMR Biomed."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.109.197830","article-title":"Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle","volume":"104","author":"Anisimov","year":"2009","journal-title":"Circ. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbabio.2010.02.016","article-title":"Redox-optimized ROS balance: a unifying hypothesis","volume":"1797","author":"Aon","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/CAD.0b013e3283293fd4","article-title":"Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer","volume":"20","author":"Aprile","year":"2009","journal-title":"Anticancer. Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6353469","DOI":"10.1155\/2016\/6353469","article-title":"Novel perspectives in redox biology and pathophysiology of failing myocytes: modulation of the intramyocardial redox milieu for therapeutic interventions-a review article from the working group of cardiac cell biology, italian society of cardiology","volume":"2016","author":"Arcaro","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/cvr\/19.6.378","article-title":"Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms","volume":"19","author":"Arnolda","year":"1985","journal-title":"Cardiovasc. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1161\/01.CIR.0000130917.12959.04","article-title":"Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts","volume":"109","author":"Asanuma","year":"2004","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"H1271","DOI":"10.1152\/ajpheart.00517.2014","article-title":"ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity","volume":"309","author":"Belmonte","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5698931","DOI":"10.1155\/2016\/5698931","article-title":"Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant Paradox?","volume":"2016","author":"Biswas","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1385\/CT:3:4:319","article-title":"Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity","volume":"3","author":"Boucek","year":"2003","journal-title":"Cardiovasc. Toxicol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"B21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11936-016-0452-z","article-title":"Anti-VEGF-induced hypertension: a review of pathophysiology and treatment options","volume":"18","author":"Brinda","year":"2016","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/bcp.12429","article-title":"Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients","volume":"78","author":"Broeyer","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/14740338.2015.986092","article-title":"Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy","volume":"14","author":"Bronte","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.110.957332","article-title":"Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation","volume":"122","author":"Bry","year":"2010","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.2459\/JCM.0000000000000382","article-title":"Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies","volume":"17","author":"Cadeddu","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am. Heart J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1111\/bph.13791","article-title":"Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction","volume":"174","author":"Cappetta","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2012.02.009","article-title":"Personal omics profiling reveals dynamic molecular and medical phenotypes","volume":"148","author":"Chen","year":"2012","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","article-title":"Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics","volume":"106","author":"Cheng","year":"2010","journal-title":"Circ. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"187r","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cjca.2014.11.020","article-title":"Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function","volume":"31","author":"Chotenimitkhun","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br. J. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","article-title":"Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy","author":"Coppini","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"B37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bbabio.2013.11.007","article-title":"Redox-optimized ROS balance and the relationship between mitochondrial respiration and ROS","volume":"1837","author":"Cortassa","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"B38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1160\/TH15-11-0842","article-title":"Cancer after intense and prolonged antiplatelet therapies\u2013fact or fiction?","volume":"114","author":"De Caterina","year":"2015","journal-title":"Thromb. Haemost."},{"key":"B41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy","volume":"106","author":"De Keulenaer","year":"2010","journal-title":"Circ. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/j.ejca.2007.06.024","article-title":"111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity","volume":"43","author":"de Korte","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1093\/jxb\/erv099","article-title":"ROS and RNS in plant physiology: an overview","volume":"66","author":"Del R\u00edo","year":"2015","journal-title":"J. Exp. Bot."},{"key":"B44","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","article-title":"Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart","volume":"44","author":"de Nigris","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/2193-1801-2-198","article-title":"Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate","volume":"2","author":"Dess\u00ed","year":"2013","journal-title":"Springerplus"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3892\/etm.2011.305","article-title":"Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction","volume":"2","author":"Dess\u00ed","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.yjmcc.2008.10.010","article-title":"Ventricular ErbB2\/ErbB4 activation and downstream signaling in pacing-induced heart failure","volume":"46","author":"Doggen","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/stem.734","article-title":"Vascular endothelial growth factor stimulates endothelial colony forming cells proliferation and tubulogenesis by inducing oscillations in intracellular Ca2+ concentration","volume":"29","author":"Dragoni","year":"2011","journal-title":"Stem Cells."},{"key":"B49","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/ncb3149","article-title":"ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation","volume":"17","author":"D'Uva","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.redox.2017.05.007","article-title":"European contribution to the study of ROS: a summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)","volume":"13","author":"Egea","year":"2017","journal-title":"Redox Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the european society of cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1200\/JCO.2010.30.6274","article-title":"Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction","volume":"28","author":"Ewer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.2007.14.8742","article-title":"Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?","volume":"26","author":"Ewer","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/rej.2010.1141","article-title":"Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention","volume":"14","author":"Ferroni","year":"2011","journal-title":"Rejuvenat. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity","volume":"111","author":"Fisher","year":"2005","journal-title":"Circulation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1096\/fj.03-0724rev","article-title":"The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage","volume":"18","author":"Fogli","year":"2004","journal-title":"FASEB J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"B60","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1586\/erc.09.15","article-title":"Role of carvedilol controlled-release in cardiovascular disease","volume":"7","author":"Fonarow","year":"2009","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0167-5273(94)90061-2","article-title":"Properties of G-protein modulated receptor-adenylyl cyclase system in myocardium of spontaneously hypertensive rats treated with adriamycin","volume":"44","author":"Fu","year":"1994","journal-title":"Int. J. Cardiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nut.2012.02.014","article-title":"Role of antioxidants in cancer therapy","volume":"29","author":"Fuchs-Tarlovsky","year":"2013","journal-title":"Nutrition"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-06-3721","article-title":"Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury","volume":"67","author":"Gabrielson","year":"2007","journal-title":"Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1168556","DOI":"10.1080\/2162402X.2016.1168556","article-title":"The immune network in thyroid cancer","volume":"5","author":"Galdiero","year":"2016","journal-title":"Oncoimmunology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e000773","DOI":"10.1161\/JAHA.113.000773","article-title":"Anti-remodeling and anti-fibrotic effects of the neuregulin-1\u03b2 glial growth factor 2 in a large animal model of heart failure","volume":"3","author":"Galindo","year":"","journal-title":"J. Am. Heart Assoc."},{"key":"B67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11897-013-0176-2","article-title":"Neuregulin as a heart failure therapy and mediator of reverse remodeling","volume":"11","author":"Galindo","year":"","journal-title":"Curr. Heart Fail. Rep."},{"key":"B68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fphar.2014.00025","article-title":"The role of iron in anthracycline cardiotoxicity","volume":"5","author":"Gammella","year":"2014","journal-title":"Front. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jacc.2009.12.044","article-title":"A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure","volume":"55","author":"Gao","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/156652412800792543","article-title":"Biomarkers of protein oxidation in human disease","volume":"12","author":"Garcia-Garcia","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.bbamcr.2016.01.021","article-title":"New signal transduction paradigms in anthracycline-induced cardiotoxicity","volume":"1863","author":"Ghigo","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"B72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10495-007-0718-8","article-title":"Cardiolipin: setting the beat of apoptosis","volume":"12","author":"Gonzalvez","year":"2007","journal-title":"Apoptosis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0301-4622(90)80012-V","article-title":"Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity","volume":"35","author":"Goormaghtigh","year":"1990","journal-title":"Biophys. Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1074\/jbc.M804570200","article-title":"Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways","volume":"284","author":"Gordon","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1200\/JCO.2009.22.9427","article-title":"Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study","volume":"28","author":"Goss","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1345\/aph.1L426","article-title":"Intricacies of bevacizumab-induced toxicities and their management","volume":"43","author":"Gressett","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"B79","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1172\/JCI57426","article-title":"Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved","volume":"122","author":"Gupta","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e74675","DOI":"10.1371\/journal.pone.0074675","article-title":"Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity","volume":"8","author":"Gupta","year":"2013","journal-title":"PLoS ONE"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"B82","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.taap.2010.08.026","article-title":"The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro","volume":"249","author":"Hasinoff","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","article-title":"Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training","volume":"15","author":"Haykowsky","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.phrs.2014.11.003","article-title":"Chronic heart damage following doxorubicin treatment is alleviated by lovastatin","volume":"91","author":"Henninger","year":"2015","journal-title":"Pharmacol. Res."},{"key":"B85","first-page":"97","article-title":"The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia","volume":"32","author":"Horacek","year":"2010","journal-title":"Exp. Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/cvr\/cvq148","article-title":"Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway","volume":"87","author":"Horie","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/CIRCULATIONAHA.109.902221","article-title":"Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice","volume":"121","author":"Huang","year":"2010","journal-title":"Circulation"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1038\/cddis.2011.65","article-title":"Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity","volume":"2","author":"Huelsenbeck","year":"2011","journal-title":"Cell Death Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B92","first-page":"382","article-title":"Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats","volume":"60","author":"Iqbal","year":"2008","journal-title":"Pharmacol. Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/eurjhf\/hfq152","article-title":"Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses","volume":"13","author":"Jabbour","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"B94","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"B95","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jjcc.2013.03.018","article-title":"Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy","volume":"62","author":"Jin","year":"2013","journal-title":"J. Cardiol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","article-title":"Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase","volume":"2","author":"Kerkela","year":"2009","journal-title":"Clin. Transl. Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer."},{"key":"B104","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1752-1947-8-220","article-title":"Gemcitabine-induced cardiomyopathy: a case report and review of the literature","volume":"8","author":"Khan","year":"2014","journal-title":"J. Med. Case Rep."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1089\/ars.2014.6124","article-title":"New redox-related arrows in the arsenal of cardiac disease treatment","volume":"21","author":"Kirk","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"B106","doi-asserted-by":"publisher","first-page":"917606","DOI":"10.1155\/2015\/917606","article-title":"Exercise prevention of Cardiovascular disease in breast cancer survivors","volume":"2015","author":"Kirkham","year":"2015","journal-title":"J. Oncol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/emmm.201303147","article-title":"VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart","volume":"6","author":"Kivel\u00e4","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000331645","article-title":"Clinical and electrocardiography changes in patients treated with capecitabine","volume":"57","author":"Koca","year":"2011","journal-title":"Chemotherapy"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIRCULATIONAHA.109.914911","article-title":"Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes","volume":"121","author":"Kohlhaas","year":"2010","journal-title":"Circulation."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1124\/jpet.110.170191","article-title":"Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect","volume":"334","author":"Koka","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"H586","DOI":"10.1152\/ajpheart.1993.265.2.H586","article-title":"Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries","volume":"265","author":"Ku","year":"1993","journal-title":"Am. J. Physiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","volume":"113","author":"Ky","year":"2013","journal-title":"Circ. Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(00)00256-4","article-title":"Role of nitric oxide in carcinogenesis and tumour progression","volume":"2","author":"Lala","year":"2001","journal-title":"Lancet Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.toxlet.2014.03.018","article-title":"A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives","volume":"227","author":"Lamberti","year":"2014","journal-title":"Toxicol. Lett."},{"key":"B116","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/ATVBAHA.108.181610","article-title":"NADPH oxidases: functions and pathologies in the vasculature","volume":"30","author":"Lass\u00e8gue","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/01.CIR.0000114521.88547.5E","article-title":"Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase","volume":"109","author":"Lemmens","year":"2004","journal-title":"Circulation"},{"key":"B118","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yjmcc.2015.12.021","article-title":"Cardioprotective effects of inorganic nitrate\/nitrite in chronic anthracycline cardiotoxicity: comparison with dexrazoxane","volume":"91","author":"Lencov\u00e1-Popelov\u00e1","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1524-4741.2011.01120.x","article-title":"Capecitabine (and 5 fluorouracil) cardiotoxicity. Metabolic considerations","volume":"17","author":"Lestuzzi","year":"2011","journal-title":"Breast J."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann. Oncol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/01.HYP.0000215283.53943.39","article-title":"Microvascular plasticity and experimental heart failure","volume":"47","author":"L\u00e9vy","year":"2006","journal-title":"Hypertension"},{"key":"B122","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1475-2840-10-69","article-title":"Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats","volume":"10","author":"Li","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1161\/01.CIR.102.17.2105","article-title":"Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol","volume":"102","author":"Li","year":"2000","journal-title":"Circulation"},{"key":"B124","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1093\/eurheartj\/ehv132","article-title":"Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction","volume":"36","author":"Lim","year":"2015","journal-title":"Eur. Heart J."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Continuous versus bolus infusion of doxorubicin in children with all: long-term cardiac outcomes","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jacc.2006.05.057","article-title":"Neuregulin-1\/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy","volume":"48","author":"Liu","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/all.12862","article-title":"Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema","volume":"71","author":"Loffredo","year":"2016","journal-title":"Allergy"},{"key":"B128","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e40763","DOI":"10.1371\/journal.pone.0040763","article-title":"Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice","volume":"7","author":"Ma","year":"2012","journal-title":"PLoS ONE"},{"key":"B130","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijcard.2015.04.232","article-title":"Cardioprotection by gene therapy: a review paper on behalf of the working group on drug cardiotoxicity and cardioprotection of the Italian Society of Cardiology","volume":"191","author":"Madonna","year":"","journal-title":"Int. J. Cardiol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10741-015-9497-4","article-title":"Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection","volume":"20","author":"Madonna","year":"","journal-title":"Heart Fail. Rev."},{"key":"B132","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"B133","doi-asserted-by":"publisher","first-page":"XI","DOI":"10.1159\/000352074","article-title":"Angiogenesis, lymphangiogenesis and clinical implications. Preface","volume":"99","author":"Marone","year":"2014","journal-title":"Chem. Immunol. Allergy"},{"key":"B134","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tox.2008.10.011","article-title":"Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy","volume":"255","author":"Martin","year":"2009","journal-title":"Toxicology"},{"key":"B135","doi-asserted-by":"publisher","first-page":"H332","DOI":"10.1152\/ajpheart.00727.2009","article-title":"Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction","volume":"299","author":"Maslov","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S0024-3205(99)00362-8","article-title":"Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats","volume":"65","author":"Matsui","year":"1999","journal-title":"Life Sci."},{"key":"B137","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10741-016-9564-5","article-title":"Current views on anthracycline cardiotoxicity","volume":"21","author":"Mele","year":"","journal-title":"Heart Fail. Rev."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.2459\/JCM.0000000000000378","article-title":"Pathophysiology of anthracycline cardiotoxicity","volume":"17","author":"Mele","year":"","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B139","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1517\/14740338.2011.589834","article-title":"Anthracycline cardiotoxicity","volume":"11","author":"Menna","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"B140","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1021\/tx800002r","article-title":"Cardiotoxicity of antitumor drugs","volume":"21","author":"Menna","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","article-title":"Models of heart failure based on the cardiotoxicity of anticancer drugs","volume":"22","author":"Mercurio","year":"2016","journal-title":"J. Card. Fail."},{"key":"B143","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.redox.2015.05.008","article-title":"Redox regulation of genome stability by effects on gene expression, epigenetic pathways and DNA damage\/repair","volume":"5","author":"Mikhed","year":"2015","journal-title":"Redox Biol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/jpet.113.204057","article-title":"Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs","volume":"346","author":"Minotti","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B146","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"B147","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.110.165860","article-title":"Pharmacological foundations of cardio-oncology","volume":"334","author":"Minotti","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/cancers2031717","article-title":"5-fu metabolism in cancer and orally-administrable 5-fu drugs","volume":"2","author":"Miura","year":"2010","journal-title":"Cancers"},{"key":"B149","doi-asserted-by":"publisher","first-page":"138148","DOI":"10.1155\/2015\/138148","article-title":"Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs","volume":"2015","author":"Molinaro","year":"2015","journal-title":"Biomed Res. Int."},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","author":"Moloney","year":"2017","journal-title":"Semin. Cell Dev. Biol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/nm.4153","article-title":"NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages","volume":"22","author":"Moon","year":"2016","journal-title":"Nat. Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11906-011-0206-y","article-title":"Mechanisms of antiangiogenic-induced arterial hypertension","volume":"13","author":"Mourad","year":"2011","journal-title":"Curr. Hypertens. Rep."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1093\/eurheartj\/ehv305","article-title":"Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications","volume":"36","author":"M\u00fcnzel","year":"2015","journal-title":"Eur. Heart J."},{"key":"B157","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1161\/01.CIR.0000018605.14470.DD","article-title":"Carvedilol decreases elevated oxidative stress in human failing myocardium","volume":"105","author":"Nakamura","year":"2002","journal-title":"Circulation"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"B160","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1089\/ars.2010.3198","article-title":"Nitric oxide\/reactive oxygen species generation and nitroso\/redox imbalance in heart failure: from molecular mechanisms to therapeutic implications","volume":"14","author":"Nediani","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur. J. Cance."},{"key":"B162","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.yjmcc.2014.03.011","article-title":"Mitochondrial reactive oxygen species production and elimination","volume":"73","author":"Nickel","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.freeradbiomed.2015.01.028","article-title":"Oxidative stress alters global histone modification and DNA methylation","volume":"82","author":"Niu","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"B164","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2459\/JCM.0000000000000379","article-title":"Role of biomarkers in monitoring antiblastic cardiotoxicity","volume":"17","author":"Novo","year":"","journal-title":"J. Cardiovasc. Med. (Hagerstown)."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1161\/CIRCRESAHA.112.267286","article-title":"Neuregulin in cardiovascular development and disease","volume":"111","author":"Odiete","year":"2012","journal-title":"Circ. Res."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCRESAHA.114.300507","article-title":"Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure","volume":"114","author":"Oka","year":"2014","journal-title":"Circ. Res."},{"key":"B168","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4172\/1948-5956.1000184","article-title":"Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography","volume":"5","author":"Oliveira","year":"2013","journal-title":"J. Cancer Sci. Ther."},{"key":"B169","doi-asserted-by":"publisher","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B170","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jjco\/hyh047","article-title":"Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil\/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers","volume":"34","author":"Oztop","year":"2004","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1089\/ars.2010.3245","article-title":"Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling","volume":"14","author":"Pagliaro","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1111\/bph.12975","article-title":"Redox signalling and cardioprotection: translatability and mechanism","volume":"172","author":"Pagliaro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bph.13005","article-title":"Pharmacology of the 'gasotransmitters' NO, CO and H2S: translational opportunities","volume":"172","author":"Papapetropoulos","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/1535370214522935","article-title":"Protein S-nitrosylation in preconditioning and postconditioning","volume":"239","author":"Penna","year":"2014","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"B175","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mito.2016.07.005","article-title":"Cardiac cytochrome c and cardiolipin depletion during anthracycline-induced chronic depression of mitochondrial function","volume":"30","author":"Pereira","year":"2016","journal-title":"Mitochondrion"},{"key":"B176","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12885-016-2409-8","article-title":"TAS-102, the first \u201ccardio-gentle\u201d fluoropyrimidine in the colorectal cancer landscape?","volume":"16","author":"Petrelli","year":"2016","journal-title":"BMC Cancer"},{"key":"B177","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"e12733","DOI":"10.1371\/journal.pone.0012733","article-title":"Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation","volume":"5","author":"Pointon","year":"2010","journal-title":"PLoS ONE"},{"key":"B179","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"B180","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1464-410X.2012.11134.x","article-title":"Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes","volume":"110","author":"Rainer","year":"2012","journal-title":"BJU Int."},{"key":"B183","doi-asserted-by":"publisher","first-page":"13144","DOI":"10.1073\/pnas.1616168113","article-title":"VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection","volume":"113","author":"R\u00e4s\u00e4nen","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B184","doi-asserted-by":"publisher","first-page":"H2149","DOI":"10.1152\/ajpheart.00728.2008","article-title":"Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure","volume":"295","author":"Rastogi","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.bjc.6603781","article-title":"Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity","volume":"96","author":"Rephaeli","year":"2007","journal-title":"Br. J. Cancer."},{"key":"B187","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res."},{"key":"B188","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/01.CIR.100.4.407","article-title":"Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors","volume":"100","author":"Rohrbach","year":"1999","journal-title":"Circulation"},{"key":"B189","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/bs.ircmb.2015.07.004","article-title":"New insight into the role of Reactive Oxygen Species (ROS) in cellular signal-transduction processes","volume":"319","author":"Russell","year":"2015","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1054\/jcaf.2002.129232","article-title":"Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure","volume":"8","author":"Sabbah","year":"2002","journal-title":"J. Card. Fail."},{"key":"B191","doi-asserted-by":"publisher","first-page":"H3720","DOI":"10.1152\/ajpheart.00436.2007","article-title":"Redox-dependent coronary metabolic dilation","volume":"293","author":"Saitoh","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2217\/FCA.15.35","article-title":"Managing anthracycline-induced cardiotoxicity: beginning with the end in mind","volume":"11","author":"Salvatorelli","year":"2015","journal-title":"Future Cardiol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B194","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1006\/taap.2002.9532","article-title":"Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy","volume":"185","author":"Santos","year":"2002","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure","volume":"368","author":"Sawyer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B196","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"B197","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1161\/CIRCULATIONAHA.111.021774","article-title":"Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms","volume":"124","author":"Scott","year":"2011","journal-title":"Circulation"},{"key":"B198","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/j.seminoncol.2013.01.001","article-title":"Exercise therapy as treatment for cardiovascular and oncologic disease after a diagnosis of early-stage cancer","volume":"40","author":"Scott","year":"2013","journal-title":"Semin. Oncol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"B200","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"B201","first-page":"145","article-title":"Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group","volume":"3","author":"Seymour","year":"1999","journal-title":"Cancer Prev. Control."},{"key":"B202","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.163.3.1602","article-title":"A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils","volume":"163","author":"Shinkai","year":"1999","journal-title":"J. Immunol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/107327480401100107","article-title":"5-fluorouracil-induced coronary vasospasm","volume":"11","author":"Shoemaker","year":"2004","journal-title":"Cancer Control."},{"key":"B204","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"Simunek","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"B205","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/mnfr.201500945","article-title":"Combination chemoprevention with grape antioxidants","volume":"60","author":"Singh","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"key":"B206","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science."},{"key":"B207","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B208","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijcard.2005.08.061","article-title":"Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats","volume":"110","author":"Soga","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5603\/CJ.2012.0084","article-title":"5-fluorouracil induced cardiotoxicity: review of the literature","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol. J."},{"key":"B210","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro","volume":"37","author":"Spallarossa","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1189\/jlb.3HI1214-584R","article-title":"Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors","volume":"99","author":"Staiano","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"B212","first-page":"39","article-title":"Exercise as prescription therapy: benefits in cancer and hypertensive patients","volume":"11","author":"Stefani","year":"2015","journal-title":"Transl Med UniSa."},{"key":"B213","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1089\/ars.2012.4795","article-title":"Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection","volume":"18","author":"Sterba","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur. Heart J."},{"key":"B215","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","article-title":"Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study","volume":"18","author":"Swain","year":"2013","journal-title":"Oncologist"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00432-003-0498-7","article-title":"The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review","volume":"130","author":"Swain","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/cvr\/cvv274","article-title":"Bidirectional cross-regulation between ErbB2 and beta-adrenergic signalling pathways","volume":"109","author":"Sysa-Shah","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"B220","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","article-title":"Role of oxidative stress in cardiac hypertrophy and remodeling","volume":"49","author":"Takimoto","year":"2007","journal-title":"Hypertension"},{"key":"B221","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K","article-title":"Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia","volume":"20","author":"Tan","year":"1967","journal-title":"Cancer"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","article-title":"Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate","volume":"19","author":"Telli","year":"2008","journal-title":"Ann. Oncol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genomics."},{"key":"B224","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.yjmcc.2006.08.002","article-title":"Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes","volume":"41","author":"Timolati","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6930","article-title":"From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview","author":"Tocchetti","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"B226","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ejhf.50","article-title":"Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction","volume":"16","author":"Tocchetti","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"B227","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","article-title":"The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors","volume":"15","author":"Tocchetti","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"B228","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2174\/1389450116666150304103517","article-title":"nitroso-redox balance and modulation of basal myocardial function: an update from the Italian Society of Cardiovascular Research (SIRC)","volume":"16","author":"Tocchetti","year":"","journal-title":"Curr. Drug Targets."},{"key":"B229","first-page":"A338","article-title":"Cardiac overexpression of creatine kinase improves cardiomyocytes function in heart failure and during increased redox stress","volume":"117","author":"Tocchetti","year":"","journal-title":"Circ. Res."},{"key":"B230","doi-asserted-by":"publisher","first-page":"H37","DOI":"10.1152\/ajpheart.01057.2004","article-title":"Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply","volume":"289","author":"Tokarska-Schlattner","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2010.29.5436","article-title":"Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Van Cutsem","year":"2002","journal-title":"Ann. Oncol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.yjmcc.2013.05.009","article-title":"MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative\/nitrative stress and subsequent dysfunction in the heart","volume":"62","author":"Varga","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fimmu.2017.00424","article-title":"Are Mast Cells MASTers in Cancer?","volume":"8","author":"Varricchi","year":"","journal-title":"Front. Immunol."},{"key":"B235","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"","journal-title":"ESMO Open"},{"key":"B236","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/exd.13107","article-title":"Controversial role of mast cells in skin cancers","volume":"26","author":"Varricchi","year":"","journal-title":"Exp. Dermatol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","article-title":"Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology","volume":"136","author":"Varricchi","year":"","journal-title":"Circulation"},{"key":"B238","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00280-013-2260-4","article-title":"The role of antioxidants in the era of cardiooncology","volume":"72","author":"Vincent","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"14554","DOI":"10.1074\/jbc.M509507200","article-title":"Nitric oxide inhibits peroxidase activity of cytochrome c.cardiolipin complex and blocks cardiolipin oxidation","volume":"281","author":"Vlasova","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B240","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejcb.2017.03.003","article-title":"Mitochondrial reactive oxygen species are involved in chemoattractant-induced oxidative burst and degranulation of human neutrophils in vitro","volume":"96","author":"Vorobjeva","year":"2017","journal-title":"Eur. J. Cell Biol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/cvr\/cvs356","article-title":"Increased expression of microRNA-146a decreases myocardial ischaemia\/reperfusion injury","volume":"97","author":"Wang","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"B242","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1172\/JCI70212","article-title":"Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer","volume":"123","author":"Welti","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B243","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1106180","article-title":"Proteotoxicity and cardiac dysfunction\u2013Alzheimer's disease of the heart?","volume":"368","author":"Willis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B244","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jacc.2015.04.071","article-title":"Intracoronary cytoprotective gene therapy: a study of VEGF-B167 in a pre-clinical animal model of dilated cardiomyopathy","volume":"66","author":"Woitek","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.niox.2012.03.006","article-title":"Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications","volume":"26","author":"Xi","year":"2012","journal-title":"Nitric Oxide."},{"key":"B246","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.mehy.2004.09.015","article-title":"Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property","volume":"64","author":"Yamagishi","year":"2005","journal-title":"Med. Hypotheses."},{"key":"B247","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00395-012-0267-3","article-title":"Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway","volume":"107","author":"Yao","year":"2012","journal-title":"Basic Res. Cardiol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"B250","doi-asserted-by":"publisher","first-page":"e102758","DOI":"10.1371\/journal.pone.0102758","article-title":"Oxaliplatin neurotoxicity involves peroxisome alterations. PPARgamma agonism as preventive pharmacological approach","volume":"9","author":"Zanardelli","year":"2014","journal-title":"PLoS ONE"},{"key":"B251","doi-asserted-by":"publisher","first-page":"e30353","DOI":"10.1371\/journal.pone.0030353","article-title":"Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis","volume":"7","author":"Zang","year":"2012","journal-title":"PLoS ONE"},{"key":"B252","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1089\/ars.2012.4550","article-title":"NADPH oxidases in heart failure: poachers or gamekeepers?","volume":"18","author":"Zhang","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"B254","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1158\/0008-5472.CAN-10-2664","article-title":"Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphys.2018.00167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T13:12:48Z","timestamp":1693573968000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphys.2018.00167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":254,"alternative-id":["10.3389\/fphys.2018.00167"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2018.00167","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"article-number":"167"}}